Novo Nordisk and Hims & Hers Health are preparing to unveil a partnership to sell obesity drugs together, a report said, a development that would end a legal clash between the Danish pharmaceutical company and the U.S. telehealth firm. The report indicated the announcement could come as soon as Monday.
The plan represents a pivot away from a previously adversarial relationship. Novo Nordisk is the manufacturer of Wegovy and Ozempic, high-profile medicines used in weight-loss and diabetes treatment. Hims & Hers had been offering compounded forms of semaglutide - the active ingredient in those branded therapies - through its telehealth platform, a practice that drew scrutiny from Novo Nordisk as it sought to protect its branded products.
Under the prospective deal, the two companies would work together on distributing obesity medications instead of continuing to resolve their differences through legal channels. The commercial specifics of the agreement were not included in the report, leaving terms and operational details undisclosed.
The move could reframe how the medications reach patients via telehealth channels and traditional distribution, although the report did not provide information on how sales, pricing, or clinical workflows will be handled. Both companies are publicly traded - Novo Nordisk on the New York Stock Exchange under the ticker NVO, and Hims & Hers Health under HIMS.
Context and implications
- This development ends an active legal dispute between the two firms, according to the report.
- It shifts the dynamic from litigation to commercial cooperation on medications that rely on semaglutide as their active ingredient.
- Key commercial and operational terms have not been disclosed, leaving open questions about distribution mechanics and competitive effects.
The report offers a factual outline of the agreement and its immediate significance but does not supply further details on the partnership's structure, financial terms, or how it will affect patients and providers. That absence of disclosed terms creates uncertainty about the exact commercial and market impact.